Youngstown / Columbus Edition
10-8 NEWS

"We follow an America‑first approach, prioritizing truth, community, and national values."

HEADQUARTERED IN COLUMBUS • SERVING 88 OHIO COUNTIES

FDA Adds Rare Vision Loss Warning to Ozempic, Wegovy and Similar Drugs

November 16, 2026

The Food and Drug Administration announced Monday, November 9, that all GLP 1 drugs, the popular medications used for diabetes and weight loss, must carry a new warning about a rare eye condition that can cause permanent vision loss. The class includes about a dozen products, among them Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity.

The condition, called nonarteritic anterior ischemic optic neuropathy or NAION, happens when blood flow to the optic nerve drops, causing sudden, painless vision loss, usually in one eye. The FDA began looking into it after a 2024 study tied it to semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy.

An FDA review of more than 125 clinical trials found the condition in roughly 6 of every 100,000 patients who took a GLP 1 drug for at least a year, compared with fewer than 4 per 100,000 among people on a placebo or other diabetes medicines. The agency stressed that the risk is rare.

Patients who notice blurred vision, blind spots or changes in how colors look should contact a health care professional right away. People who have had NAION should talk with their doctor about whether to keep taking the medication, and the FDA told doctors to consider stopping the drug in patients who develop it unless the benefits clearly outweigh the risk.

Sources